Cabaletta Bio, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Cabaletta Bio, Inc. has filed its annual 10-K report for the fiscal year ended December 31, 2023, detailing its business operations and financial standing.</b>

AI Summary

Cabaletta Bio, Inc. (CABA) filed a Annual Report (10-K) with the SEC on March 21, 2024. Cabaletta Bio, Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Delaware and headquartered in Philadelphia, PA. The filing covers the period ending December 31, 2023. The SIC code for the company is 2836, Biological Products (No Diagnostic Substances). The filing number is 001-39103.

Why It Matters

For investors and stakeholders tracking Cabaletta Bio, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Cabaletta Bio's financial health, operational activities, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. As a biotechnology company, understanding its regulatory compliance, product development pipeline, and financial resources detailed in this report is vital for stakeholders evaluating investment opportunities and risks.

Risk Assessment

Risk Level: medium — Cabaletta Bio, Inc. shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and significant R&D costs, as indicated by its SIC code and the nature of its business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Cabaletta Bio's current financial position and potential challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
• 2024-03-21 — Filing Date (FILED AS OF DATE)
• 2836 — SIC Code (STANDARD INDUSTRIAL CLASSIFICATION)
• 001-39103 — SEC File Number (SEC FILE NUMBER)

Key Players & Entities

• Cabaletta Bio, Inc. (company) — FILER
• 20231231 (date) — CONFORMED PERIOD OF REPORT
• 20240321 (date) — FILED AS OF DATE
• 001-39103 (other) — SEC FILE NUMBER
• 2836 (other) — STANDARD INDUSTRIAL CLASSIFICATION
• DE (other) — STATE OF INCORPORATION
• PA (other) — STATE
• 2929 ARCH STREET (address) — BUSINESS ADDRESS

FAQ

Industry Context

Cabaletta Bio, Inc. operates in the biotechnology sector, focusing on the development of novel therapies. This sector is characterized by significant research and development investments, long product development timelines, and stringent regulatory oversight.

Regulatory Implications

As a biotechnology company, Cabaletta Bio is subject to regulations from bodies such as the Food and Drug Administration (FDA) concerning drug development, clinical trials, and marketing approvals. Compliance with these regulations is critical for the company's operations and product lifecycle.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
2. Analyze the risk factors section to understand potential challenges and uncertainties facing Cabaletta Bio.
3. Compare the company's performance and disclosures in this 10-K with previous filings and industry peers.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-21: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the annual 10-K for the fiscal year 2023, providing a comprehensive update compared to previous quarterly (10-Q) or current reports (8-K).

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se

Filing Documents

• caba-20231231.htm (10-K) — 2669KB
• caba-ex4_3.htm (EX-4.3) — 62KB
• caba-ex10_19.htm (EX-10.19) — 16KB
• caba-ex21_1.htm (EX-21.1) — 1KB
• caba-ex23_1.htm (EX-23.1) — 9KB
• caba-ex31_1.htm (EX-31.1) — 14KB
• caba-ex31_2.htm (EX-31.2) — 14KB
• caba-ex32_1.htm (EX-32.1) — 8KB
• caba-ex32_2.htm (EX-32.2) — 8KB
• caba-ex99_7.htm (EX-99.7) — 39KB
• img62972014_0.jpg (GRAPHIC) — 37KB
• img62972014_1.jpg (GRAPHIC) — 80KB
• img62972014_2.jpg (GRAPHIC) — 78KB
• img62972014_3.jpg (GRAPHIC) — 287KB
• img62972014_4.jpg (GRAPHIC) — 16KB
• 0000950170-24-034422.txt (&nbsp;) — 10125KB
• caba-20231231.xsd (EX-101.SCH) — 1103KB
• caba-20231231_htm.xml (XML) — 1381KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 40 Item 1B. Unresolved Staff Comments 99 Item 1C. Cybersecurity 100 Item 2.

Properties

Properties 100 Item 3.

Legal Proceedings

Legal Proceedings 100 Item 4. Mine Safety Disclosures 100 PART II 101 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 101 Item 6. Reserved 101 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 102 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 116 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 116 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 116 Item 9A.

Controls and Procedures

Controls and Procedures 117 Item 9B. Other Information 118 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 119 PART III 120 Item 10. Directors, Executive Officers and Corporate Governance 120 Item 11.

Executive Compensation

Executive Compensation 120 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 120 Item 13. Certain Relationships and Related Transactions, and Director Independence 120 Item 14. Principal Accounting Fees and Services 120 PART IV 121 Item 15. Exhibits, Financial Statement Schedules 121 Item 16 Form 10-K Summary 121

Signatures

Signatures 123 i Summary of the Material and Other Risks Associated with Our Business We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We are highly dependent on our relationships with University of Pennsylvania, or Penn, and/or WuXi Advanced Therapies, Inc., or WuXi, for our current manufacturing needs for our Phase 1/2 RESET TM , or Restoring Self-Tolerance, clinical trials for CABA-201, our Phase 1 clinical trial of DSG3-CAART, or the DesCAARTes TM trial, and our Phase 1 clinical trial of MuSK-CAART, or the MusCAARTes TM trial, and if Penn's or WuXi's manufacturing capacity is reduced or otherwise delayed or limited, including due to legislative action, this could adversely impact enrollment in our trials. We are reliant on intellectual property licensed to us by Penn and Nanjing IASO Biotherapeutics Co., Ltd., or IASO, and termination of one of these license agreements would result in the loss of significant rights, which would have a material adverse effect on our business. If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets. We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales. Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. If we are unable to successfully develop our current programs into a portfolio of product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates. If we encounter difficulties

Business

Item 1. Business. Overview We are a clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA, or Cabaletta Approach to B cell Ablation, platform encompasses two strategies. Our CARTA, or Chimeric Antigen Receptor T cells for Autoimmunity, approach is designed to potentially reset the immune system. Our legacy CAART, or Chimeric AutoAntibody Receptor T cells, approach is designed to engineer T cells to selectively engage and eliminate only disease-causing B cells. We believe our CABA platform has the potential to enable complete and durable responses for a broad range of autoimmune diseases. The CARTA strategy is designed to achieve transient and complete depletion of all B cells following a single treatment by using T cells engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the complete elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy nave B cells. This approach has the potential to reset the immune system, providing meaningful durable and complete clinical responses to patients off immunosuppressive therapies. The legacy CAART strategy is designed to selectively engage and eliminate only the pathogenic B cells responsible for driving disease by using T cells engineered to express disease specific targeting domains which are designed to mimic the antigen that is the subject of attack in an autoimmune disease. Our CAARs differ from chimeric antigen receptors, or CARs, in the use of the autoantigen rather than an antibody fragment, which may enable the CAAR T cells to serve as a "decoy" for specific autoreactive B cell receptors expressed on the surface of B c

View Full Filing

View this 10-K filing on SEC EDGAR